期刊
ANTIBIOTICS-BASEL
卷 10, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/antibiotics10020124
关键词
endolysin; antibiotic resistance; bacteriophages
资金
- Zewail City of Science and Technology [ZC 019-2019]
- ASRT: Genetic Engineering and Biotechnology Grant [51/2020]
- European Commission under Horizon 2020's Marie Sklodowska-Curie Actions COFUND scheme [712754]
- Severo Ochoa program of the Spanish Ministry of Science and Competitiveness [SEV-2014-0425 (2015-2019)]
- Ministerio de Economia, Industria y Competitividad, MINECO
- Agencia Estatal de Investigacion (AEI), Spain
- Fondo Europeo de Desarrollo Regional, FEDER
- European Union [RTI2018-098573-B-100]
- CERCA programme
- AGAUR-Generalitat de Catalunya, Spain [2017SGR-1079]
- European Regional Development Fund-FEDER
- Catalan Cystic Fibrosis association, Spain
Endolysins have emerged as a potential alternative therapeutic approach against antibiotic-resistant bacterial infections, showing promising results in laboratory settings. However, further research is needed to understand their resistance, safety, and immunogenicity for in-vivo application.
Due to the global emergence of antibiotic resistance, there has been an increase in research surrounding endolysins as an alternative therapeutic. Endolysins are phage-encoded enzymes, utilized by mature phage virions to hydrolyze the cell wall from within. There is significant evidence that proves the ability of endolysins to degrade the peptidoglycan externally without the assistance of phage. Thus, their incorporation in therapeutic strategies has opened new options for therapeutic application against bacterial infections in the human and veterinary sectors, as well as within the agricultural and biotechnology sectors. While endolysins show promising results within the laboratory, it is important to document their resistance, safety, and immunogenicity for in-vivo application. This review aims to provide new insights into the synergy between endolysins and antibiotics, as well as the formulation of endolysins. Thus, it provides crucial information for clinical trials involving endolysins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据